Hakkımızda

The Founder of Cell Gene Company began research in the field of Regenerative Medicine and Cell therapy since 2005. Considering the future of cell therapy market, we have established our biotechnology companies in Iran. The vigorous work of our scientists and doctors in the field of regenerative cell therapy enabled us to develop an innovative cell based products platform for multiple potential applications in the health debilitating conditions.

Cell-Gene Company

Cell Gene Company is regenerative medicine based company that provides novel cell therapy based treatment to heal variety of complicated health problems / aesthetic demands by the use of either autologous or allogeneic cells / adult stem cells.

We continue to do our very best in the following four areas:

1. Cell therapy for incurable diseases /aesthetic problems with the highest quality cells.

2. The production of best quality synthetic and natural scaffolds.

3. Cell seeding on different scaffolds.

4. Production of stem cell derived conditioned medium and stem cell serum for therapeutic, cosmetic and laboratory purposes.

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.